US research roundup: Alnylam Pharmaceuticals, Carvana, MongoDB
MDB•Analysts revised ratings and price targets for several U.S.-listed companies. Carvana’s target was adjusted to $90 from $450 to reflect its 5-for-1 stock split, while MongoDB received four target cuts, including D.A. Davidson’s reduction to $415 from $465.
1. Selected analyst actions
The roundup highlighted target changes for Alnylam Pharmaceuticals, Carvana, Lumentum Holdings, Microsoft and MongoDB. JP Morgan cut Alnylam’s target to $369 from $375; Oppenheimer adjusted Carvana’s to $90 from $450 to reflect a 5-for-1 stock split; Bernstein initiated Lumentum coverage with an outperform rating and a $1,220 target; Piper Sandler raised Microsoft’s target to $610 from $550; and D.A. Davidson cut MongoDB’s target to $415 from $465.
2. Other MongoDB targets
Stephens cut MongoDB’s target to $372 from $398, Stifel lowered its target to $385 from $465, and UBS reduced its target to $375 from $410.
